Menopause Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Menopause is defined as the permanent cessation of menstruation following the loss of ovarian follicular activity, confirmed after 12 consecutive months of amenorrhoea in the absence of other pathological or physiological causes. The average age of natural menopause in the UK and India is 51 years. The perimenopause — the transitional phase preceding the final menstrual period — can last 4–10 years and is characterised by fluctuating oestrogen levels that produce the majority of troublesome symptoms.

Menopause treatment encompasses a spectrum of approaches aimed at alleviating vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), mood disturbance, sleep disruption, musculoskeletal symptoms, and long-term consequences of oestrogen deficiency including osteoporosis and cardiovascular risk. Modern management is highly individualised, guided by symptom burden, contraindications, personal preferences, and risk–benefit discussion anchored in the NICE Menopause Guideline NG23 (2019, updated 2023) and the British Menopause Society (BMS) 2022 consensus statement.

Premature ovarian insufficiency (POI), affecting approximately 1 in 100 women under 40, requires a different risk–benefit framework: hormone replacement therapy (HRT) is strongly recommended until the natural age of menopause (51) to mitigate excess cardiovascular and bone morbidity from prolonged oestrogen deficiency, independent of symptom burden.

Menopause treatment targets a broad range of symptoms and associated conditions:

• Vasomotor symptoms (VMS): Hot flushes and night sweats affect 70–80% of women; severe VMS significantly impairs quality of life, sleep, and work productivity. VMS are mediated by reduced norepinephrine and serotonin activity in the hypothalamic thermoregulatory centre, compounded by declining oestrogen.
• Genitourinary syndrome of menopause (GSM): Encompasses vulvovaginal atrophy, vaginal dryness, dyspareunia, recurrent urinary tract infections, urgency, and stress incontinence — affecting over 50% of postmenopausal women. Unlike VMS, GSM is progressive and does not improve without treatment.
• Hypoactive sexual desire disorder (HSDD): Reduced libido attributable in part to falling androgen levels during the menopausal transition.
• Mood and cognitive symptoms: Anxiety, low mood, and brain fog are common in perimenopause; MHT initiated in the 'window of opportunity' (within 10 years of menopause or before age 60) may have a neutral-to-beneficial cognitive effect, in contrast to the increased dementia risk suggested by the WHIMS data for older women starting oral conjugated equine estrogen.
• Musculoskeletal symptoms: Joint pain, stiffness, and increased risk of osteoporosis. Oestrogen deficiency accelerates bone turnover; MHT reduces vertebral fracture risk by ~35% and hip fracture risk by 30–40%.
• Metabolic and cardiovascular risk: Menopause accelerates atherosclerosis; transdermal MHT initiated early does not increase — and may modestly reduce — cardiovascular event risk.

Most symptomatic perimenopausal and postmenopausal women are candidates for some form of menopause treatment. Eligibility for MHT specifically requires a thorough risk assessment:

• Good candidates for systemic MHT: Women with moderate-to-severe VMS or GSM, women with POI (under 40), those at high risk of osteoporosis without contraindications, and women whose symptoms significantly impair quality of life.
• Caution/specialist review required: Personal history of oestrogen-receptor-positive breast cancer, undiagnosed vaginal bleeding, active or recent venous thromboembolism (VTE), untreated severe hypertension, active liver disease, or known BRCA mutation. Transdermal (not oral) oestrogen does not increase VTE risk and is preferred when VTE risk is a concern.
• Non-hormonal therapies indicated: Women who decline MHT, those with absolute contraindications to oestrogen, or breast cancer survivors seeking VMS relief.
• Premature ovarian insufficiency: All women with confirmed POI (FSH >25 IU/L on two occasions >4 weeks apart, age <40) should be offered HRT regardless of symptom burden, unless there is a compelling contraindication.

Menopausal status is typically confirmed clinically in women over 45 by symptom profile and menstrual history. FSH measurement is unreliable during perimenopause due to fluctuation and is not routinely recommended by NICE for diagnosis in women over 45.

Menopausal Hormone Therapy (MHT / HRT)

MHT remains the most effective treatment for VMS (reducing hot flush frequency by 75–90%) and GSM.

• Oestrogen route: Transdermal oestradiol (patches, gels, sprays) is the preferred route per NICE 2023 and BMS 2022 — it avoids first-pass hepatic metabolism, does not increase VTE or stroke risk (unlike oral preparations), and is preferred for women with obesity, migraine with aura, or cardiovascular risk factors.
• Progestogen for endometrial protection: Women with a uterus require a progestogen alongside oestrogen. Micronised progesterone (Utrogestan) — body-identical — is preferred over synthetic progestogens; it carries a more favourable breast safety profile and has anxiolytic and sleep-promoting properties. The Mirena LNG-IUS (52 mg) also provides effective endometrial protection and reduces menstrual bleeding.
• Continuous combined vs sequential MHT: Sequential MHT (oestrogen throughout the cycle, progestogen for 12–14 days/month) is used during perimenopause or in the first year post-menopause. Continuous combined MHT (both hormones daily) is standard for women >1 year post-menopause to achieve amenorrhoea.
• Testosterone for HSDD: Transdermal testosterone (AndroFeme 1% cream, compounded gel, or off-label Testogel) is evidence-supported for HSDD in postmenopausal women. Target free testosterone in the upper female physiological range. Monitoring of lipid and haematocrit levels is recommended.
• Vaginal oestrogen: Low-dose topical preparations (estriol cream, estradiol pessaries/rings, promestriene) treat GSM with minimal systemic absorption. ISSWSH 2023 consensus confirms vaginal oestrogen is safe for most breast cancer survivors experiencing GSM, including those on aromatase inhibitors, when systemic therapies are contraindicated or declined — to be discussed with the oncology team.

Non-Hormonal Pharmacological Options

• Fezolinetant (Veoza): A selective NK3 (neurokinin 3) receptor antagonist targeting the KNDy neuron pathway in the hypothalamus. FDA-approved (2023) and now available in the UK. Phase III SKYLIGHT 1, 2, 3, and 4 trials demonstrated 60–65% reduction in moderate-to-severe VMS frequency at 12 weeks vs placebo, with sustained efficacy at 52 weeks. Suitable for women who cannot or prefer not to use MHT.
• SSRIs/SNRIs: Paroxetine 7.5 mg (the only FDA-approved non-hormonal VMS drug prior to fezolinetant), venlafaxine 37.5–75 mg, desvenlafaxine, and escitalopram reduce hot flush frequency by 40–60%. Particularly useful in women with comorbid anxiety or depression. Note: paroxetine inhibits CYP2D6 and should be avoided in women on tamoxifen.
• Gabapentin: Effective for VMS and sleep disruption but limited by central nervous system side effects (dizziness, sedation).
• Oxybutynin: Anticholinergic with modest VMS efficacy; limited by dry mouth and cognitive caution in older women.
• Clonidine: Alpha-2 adrenergic agonist; modest VMS reduction, limited tolerability.

Non-Pharmacological and Lifestyle Measures

• Cognitive behavioural therapy (CBT) — NICE-endorsed for VMS and low mood; reduces hot flush problem rating even without frequency reduction.
• Mindfulness-based stress reduction (MBSR)
• Acupuncture — modest benefit in some trials
• Weight management, aerobic exercise, avoidance of VMS triggers (alcohol, spicy food, hot beverages)
• Cooling strategies: layered clothing, cooling fans, cold water

• Symptom relief: MHT reduces VMS frequency by 75–90%, improving sleep quality, work productivity, and overall quality of life.
• GSM resolution: Vaginal oestrogen reverses atrophic changes in 80–90% of women, reducing dyspareunia, dryness, and recurrent UTIs.
• Bone protection: MHT is NICE-approved for prevention and treatment of osteoporosis in women under 60. It reduces hip fracture risk by 30–40% and vertebral fracture risk by ~35%.
• Cardiovascular benefit (timing hypothesis): MHT initiated within the 'window of opportunity' (within 10 years of menopause, or before age 60) may reduce coronary heart disease risk and total mortality, consistent with observational data and supported by the KEEPS and ELITE trials.
• Mood and cognitive benefits: Resolution of sleep disruption, night sweats, and mood symptoms improves psychological well-being. Estrogen initiated early in the menopause transition has neutral-to-beneficial effects on cognitive function and mood.
• Sexual function: Combined improvement in GSM and libido (with testosterone) significantly benefits sexual health and relationship quality.
• POI-specific benefit: HRT in POI reduces long-term excess cardiovascular morbidity and mortality and preserves bone density to population norms.

MHT decisions must balance individual risks and benefits. Key safety data:

• Breast cancer risk: Combined oestrogen–progestogen MHT is associated with a small increase in breast cancer risk — approximately 4 additional cases per 1,000 women over 5 years, comparable to the risk from drinking 1–2 units of alcohol per day or being overweight. Oestrogen-only MHT (for hysterectomised women) may have a neutral or reduced breast cancer risk. Micronised progesterone carries a lower breast risk than synthetic progestogens. Risk returns to baseline within 5 years of stopping MHT.
• VTE risk: Oral oestrogen increases VTE risk approximately 2-fold. Transdermal oestradiol does not increase VTE risk and is the preferred route for women with elevated VTE risk (obesity, prior VTE, thrombophilia) — per NICE 2023.
• Stroke risk: Oral oestrogen (particularly conjugated equine estrogen) is associated with modest increased ischaemic stroke risk. Transdermal oestradiol has not been shown to increase stroke risk.
• Endometrial cancer: Oestrogen-only MHT without progestogen significantly increases endometrial hyperplasia and cancer risk in women with a uterus. Adequate progestogen (especially continuous combined regimen) eliminates this excess risk.
• Cognitive effects — WHIMS caution: The Women's Health Initiative Memory Study (WHIMS) showed increased dementia risk with oral conjugated equine estrogen + medroxyprogesterone acetate initiated in women aged 65+. This finding does not apply to transdermal body-identical MHT initiated near menopause onset.
• Other risks: Headache, nausea, breast tenderness, and irregular bleeding are common short-term side effects, usually resolving within 3 months. Fibroids may enlarge; gallstone risk is modestly increased with oral (not transdermal) oestrogen.

• Initial review: At 3 months after starting MHT to assess symptom control, tolerability, side effects, and bleeding pattern.
• Annual review: Reassess ongoing need, risk–benefit balance, blood pressure, weight, and any new health information. NICE recommends annual rather than arbitrary 5-year cut-offs for MHT continuation.
• Duration: MHT can be continued as long as the benefits outweigh the risks, informed by annual review. There is no mandatory maximum duration specified by NICE 2023.
• Bone health (DEXA): Dual-energy X-ray absorptiometry (DEXA) scan is indicated in women with POI, those with additional osteoporosis risk factors, or when considering stopping MHT after prolonged use. MHT maintains bone density while being taken; an accelerated loss phase may follow cessation.
• Breast surveillance: Women on MHT should participate in national breast screening programmes. MHT does not preclude mammography.
• Testosterone monitoring: 3–6 monthly total testosterone and SHBG levels; lipid and haematocrit monitoring every 6 months initially.
• Vaginal oestrogen: Can be continued indefinitely without progestogen in women with a uterus, as systemic absorption is negligible at licensed low doses. Symptom assessment every 6–12 months.
• Stopping MHT: Gradual dose reduction over 3–6 months is preferred over abrupt cessation to minimise rebound VMS.

The cost of menopause treatment varies widely by country, healthcare system, and treatment modality:

• UK (NHS): All licensed MHT preparations are available on NHS prescription. Standard preparations (patches, gels, Utrogestan, vaginal estriol) are affordable. As of 2023, the HRT pre-payment certificate allows women to obtain all HRT items for a single annual charge (~£31.25/year), significantly reducing out-of-pocket cost.
• India: Oestrogen patches (e.g., Climara 50 mcg) cost approximately INR 500–1,500 per pack; progesterone capsules (Susten 200) cost INR 100–300/month. Vaginal estriol (Ovestin) costs INR 200–500/tube. Fezolinetant is not yet available in India as of 2026.
• Private clinics (UK/India): Menopause specialist consultation: £150–350 (UK); INR 800–2,500 (India). Compounded testosterone preparations vary widely; licensed products are preferred for consistency.
• Non-hormonal options: Paroxetine 7.5 mg (Brisdelle) is a branded preparation — generic SSNRIs at equivalent doses are substantially cheaper. Fezolinetant (Veoza) pricing in the US is approximately $600/month without insurance; UK NHS pricing is under negotiation as of 2026.
• DEXA scan: INR 1,500–3,500 in India; £70–150 in UK private settings (free on NHS with clinical indication).

When MHT is contraindicated, declined, or insufficient, the following evidence-based alternatives are available:

• Fezolinetant (NK3 receptor antagonist): The most effective non-hormonal VMS treatment to date. Reduces moderate-to-severe hot flush frequency by 60–65% at 12 weeks (SKYLIGHT trials). Well-tolerated; transaminase monitoring recommended (rare hepatotoxicity signal in trials). Approved by FDA (2023); EU and MHRA approvals followed.
• SSRIs/SNRIs: Venlafaxine 37.5–75 mg or paroxetine (avoid with tamoxifen) reduce VMS by 40–60%. Also improve mood and sleep.
• Ospemifene: Selective estrogen receptor modulator (SERM) taken orally for GSM — improves vaginal atrophy without vaginal application. Not suitable if breast cancer history.
• Intravaginal prasterone (DHEA, Intrarosa): Locally metabolised to both oestrogen and androgen; treats GSM with minimal systemic oestrogen levels.
• Cognitive behavioural therapy (CBT): NICE-recommended for VMS and menopause-related low mood; delivered via group sessions or digital programmes (e.g., Menopause Brain App).
• Bisphosphonates / denosumab / romosozumab: First-line bone-protective treatments if MHT is not used and DEXA confirms osteoporosis or high fracture risk.
• Phytoestrogens: Isoflavones (soy, red clover) have weak, inconsistent evidence for VMS; may interact with tamoxifen. Not recommended as primary therapy by major guidelines.